Daily Stock Analysis, AXON, Axovant Sciences Ltd, priceseries

Axovant Sciences Ltd. Daily Stock Analysis
Stock Information
Open
1.30
Close
1.22
High
1.31
Low
1.20
Previous Close
1.39
Daily Price Gain
-0.17
YTD High
2.45
YTD High Date
Mar 11, 2019
YTD Low
0.93
YTD Low Date
Jan 23, 2019
YTD Price Change
0.14
YTD Gain
12.44%
52 Week High
6.59
52 Week High Date
Jun 7, 2018
52 Week Low
0.93
52 Week Low Date
Jan 23, 2019
52 Week Price Change
-0.13
52 Week Gain
-9.63%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 7. 2017
12.90
Mar 21. 2017
14.43
10 Trading Days
11.89%
Link
LONG
Apr 7. 2017
15.13
May 4. 2017
23.72
18 Trading Days
56.75%
Link
LONG
May 29. 2018
1.49
May 30. 2018
1.65
1 Trading Days
10.40%
Link
LONG
Jul 3. 2018
2.68
Jul 5. 2018
2.86
1 Trading Days
6.72%
Link
LONG
Jan 30. 2019
1.03
Feb 14. 2019
1.17
11 Trading Days
13.26%
Link
LONG
Mar 7. 2019
1.41
Mar 14. 2019
1.50
5 Trading Days
6.38%
Link
Company Information
Stock Symbol
AXON
Exchange
NYSE
Company URL
http://www.axovant.com
Company Phone
441-295-5950
CEO
David T. Hung
Headquarters
-
Business Address
20-22 BEDFORD ROW, LONDON, UNITED KINGDOM WC1R 4JS
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001636050
About

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. It offers RVT-101 product which is an orally administered therapy that improves cognition and daily functioning of dementia patients. Axovant Sciences was founded on October 31, 2014 and is headquartered in Hamilton, Bermuda.

Description

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquiring, developing, and commercializing novel therapeutics for the treatment of dementia in the United States and Europe. Its lead product candidate, intepirdine, is a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease and in Phase II clinical trial for treating dementia with Lewy bodies (DLB). The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia and REM behavior disorder in patients with DLB. In addition, it focuses on developing a pipeline of product candidates to address the cognitive, behavioral, and functional aspects of dementia. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in Hamilton, Bermuda. Axovant Sciences Ltd. is a subsidiary ofRoivant Sciences Ltd.